US FDA suggests annual reporting for low-risk manufacturing changes
This article was originally published in Scrip
Executive Summary
The US Food and Drug Administration is proposing to relax its policy on the submission of supplementary applications for minor and incremental changes to drug sponsors' manufacturing processes and controls.